Retevmo (selpercatinib) is a brand-name drug prescribed for certain types of cancer in adults and some children. Retevmo comes as an oral capsule that’s typically taken twice per day, but the dosage ...

If you have a certain thyroid or lung cancer, your doctor may prescribe Retevmo for you. It’s a prescription drug that’s used to treat the following cancers in specific situations: With advanced ...

Progression-free survival improved with Retevmo as the initial treatment for patients with advanced RET-mutant medullary thyroid cancer. Retevmo (selpercatinib) improved progression-free survival ...

Retevmo is an U.S. FDA-approved oral prescription medicine, 120 mg or 160 mg dependent on weight (<50 kg or ≥50 kg, respectively), taken twice daily until disease progression or unacceptable toxicity.

How about this for a label expansion? Two years after blessing Eli Lilly’s Retevmo to treat lung and thyroid cancers caused by a specific biomarker, the FDA has authorized the drug to be used across ...

Retevmo as a treatment for patients with advanced RET-mutant medullary thyroid cancer “is very exciting,” as treatment options were previously limited, an expert told CURE®. Treatment with Retevmo ...

Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved selpercatinib for the treatment of patients with one of three types of tumors that have RET ...

--Eli Lilly and Company today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the multikinase inhibitors cabozantinib or vandetanib as an initial ...

INDIANAPOLIS, Aug. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed ...

Results from LIBRETTO-121 showed a confirmed overall response rate of 48% (95% CI, 28-69). The Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the ...